<DOC>
	<DOCNO>NCT02616692</DOCNO>
	<brief_summary>This non-interventional cross-sectional online survey evaluate preference among patient self-reported HCC . The survey ask patient express preference regard description HCC treatment , include sorafenib ( described 'oral anti-cancer therapy ' ) , repeat transarterial chemoembolization ( TACE ) , hepatic arterial infusion chemotherapy ( HAIC ) . Please note intervention patient may receive complete online survey give regardless participation survey . Questions also include ask patient rank various treatment characteristic ( e.g. , mechanism action , risk adverse effect , etc . ) relative . The ultimate goal well understand patient perception treatment provide evidence help patient ' physician ' treatment decision-making HCC .</brief_summary>
	<brief_title>HCC Patient Preferences Japan</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>The following eligibility criterion use : Have diagnosis HCC Are &gt; 20 year age Reside Japan Are able read understand Japanese provide inform consent complete survey instrument None currently consider</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HCC</keyword>
	<keyword>Patient preference</keyword>
</DOC>